Table 4.
Associations of subclinical cardiac organ damage in the psoriasis group.
| Univariable Analyses | Multivariable Analyses | |||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| Age, years | 1.05 (1.01–1.10) | 0.02 | 1.05 (0.99–1.11) | 0.12 |
| Female sex | 1.96 (0.59–6.52) | 0.27 | 3.24 (0.66–15.86) | 0.15 |
| Hypertension | 9.10 (2.11–39.34) | 0.003 | 6.88 (1.32–35.98) | 0.02 |
| Body mass index, kg/m2 | 1.12 (1.00–1.25) | 0.06 | 1.07 (0.93–1–24) | 0.36 |
| Current smoking | 0.32 (0.10–1.05) | 0.06 | ||
| Obesity | 1.87 (0.59–5.94) | 0.29 | ||
| Diabetes | 2.08 (0.18–24.51) | 0.56 | ||
| LDL cholesterol, mmol/L | 1.81 (0.96–3.42) | 0.07 | ||
| Statin, n (%) | 2.01 (0.35–12.51) | 0.42 | ||
| Anti-hypertensive treatment | 5.87 (1.41–24.40) | 0.02 | ||
| Methotrexate | 1.01 (0.23–4.71) | 0.95 | ||
| Disease duration, months | 1.04 (0.99–1.08) | 0.11 | ||
| PASI at treatment start | 1.03 (0.97–1.08) | 0.34 | ||
| Current PASI | 1.75 (0.81–3.75) | 0.15 | ||
| DLQI at treatment start | 0.96 (0.86–1.06) | 0.38 | ||
| Current DLQI | 1.02 (0.68–1.54) | 0.92 | ||
| Psoriasis arthritis | 2.03 (0.79–5.27) | 0.14 | ||
CI: Confidence interval; DLQI: Dermatology life quality index; LDL: Low density lipoprotein; OR: Odds ratio; PASI: Psoriasis area and severity index.